Advokatfirman Lindahl acts as an adviser in Abboxia’s merger with FrostPharma
Advokatfirman Lindahl represented the sellers of Abboxia in the strategic merger with FrostPharma. The two companies are now merging under the name of FrostPharma and will thus become one of the leading specialist pharmaceutical companies with the widest range of hospital drugs in the Nordic Region.
The merger combines FrostPharma’s commercial strength and strategic alliances with Abboxia’s development capacity, thus allowing more extensive supply of hospital medicines to Nordic healthcare providers.
The Lindahl team consisted of Svante Liljedahl, Olivia Sandin and Jannica Stefansson.
About FrostPharma and Abboxia
FrostPharma, which was founded in 2016, focuses on strategic partnerships and commercialisation of specialist pharmaceuticals in the Nordic market. Abboxia, which was founded in 2017, has developed several specialist medicines for the hospital segment in the Nordic Region.
Read more in the FrostPharma press release here.
Carousel items
-
Cases and transactions
5/6/2026
Lindahl advises Equistone Partners Europe on the sale of BUKO Group
Lindahl, together with Clifford Chance, advises Equistone Partners Europe on the sale of BUKO Group to Groupe Bruxelles Lambert.
-
Knowledge
5/6/2026
A reformed environmental law – what you need to know
Swedish environmental law is undergoing a historic reform. Learn what the new Environmental Permit Authority, revised review tracks and shorter appeal chains mean for your operations – and what you need to do now.
-
News articles
5/4/2026
Johan Norderyd named Practitioner of the Year at the Managing IP Awards
Johan Norderyd has been named the winner in the Sweden Practitioner of the Year (Law Firms) category at the Managing IP EMEA Awards 2026.
-
Portraits
1/20/2026
How I use AI in my daily work as a lawyer
AI is no longer the future – it is everyday reality. Johanna Karlsson, lawyer and senior associate at Lindahl, talks about how AI tools such as Legora have become a natural part of her workflow.
-
Read more news and insights?
